Company Profile

Galera Therapeutics LLC
Profile last edited on: 5/16/2023      CAGE: 6YEU5      UEI: G61CA7K9CE35

Business Identifier: Therapeutic agents preventing damage to normal tissues during adiation treatment of cancer.
Year Founded
2009
First Award
2017
Latest Award
2020
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2 West Liberty Boulevard Suite 110
Malvern, PA 19355
   (610) 725-1511
   N/A
   www.galeratx.com
Location: Single
Congr. District: 06
County: Chester

Public Profile

Galera Therapeutics, Inc. (NASDAQ:GRTX) is a clinical stage biopharmaceutical company structured aorund the development and commercialization of therapeutics for transformation of radiotherapy in cancer. The company's lead product candidate is indicated as avasopasem manganese (GC4419), a small molecule dismutase mimetic. The completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. IThe firm is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : GRTX
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2020 2 NIH $1,093,393
Project Title: GC4419, an SOD Mimetic, as a Radiomodulator in Lung Cancer Patients Treated with SBRT

Key People / Management

  Mel Sorensen -- CEO and President

  Robert A Beardsley -- COO and Founder

  Christopher Degnan -- Chief Financial Officer

  Arthur Fratamico -- CBO

  Jon T Holmlund -- CMO

  Jeffery L Keene -- Vice President of Research

  Dennis P Riley -- CSO andFounder

  Tephen Ross -- CCO

  Joel Sussman

  Randy Weiss -- CEO

Company News

There are no news available.